Furosemide VS Torasemide

Which is gentler on the kidneys, and more beneficial for elderly heart failure patients?

Does anyone have any information about this?

reddit.com
u/Run-neR — 2 days ago

Fon satış emri iptali yapılabilir mi

dün 2 gün valörlü fon satış emri girmiştim. Bugün vazgeçtim, emri iptal etmenin bir yolu var mı? Emir iptaline basınca "ileri valorlu talimat iptal edilemez" diyor.

reddit.com
u/Run-neR — 13 days ago
▲ 3 r/AFIB

Apixaban VS Edoxaban

Are you over 80 and taking Lixiana (edoxaban) or Eliquis (apixaban), or do you know someone over 80 who has been prescribed either of these drugs?

Which medication provides greater protection for an atrial fibrillation patient over 80 years old?

reddit.com
u/Run-neR — 14 days ago
▲ 1 r/AFIB

Edoxaban versus Apixaban Outcomes Differences in 8,444 Patients with Atrial Fibrillation from Italy: A Real-World Use Comparison [2026]

ABSTRACT

Background: Based on efficacy and safety data from randomized controlled trials (RCTs) and real-world studies, direct oral anticoagulants are recommended for thromboembolism prevention in patients with atrial fibrillation (AF). However, no RCTs have compared edoxaban with apixaban. Objectives: This study aimed to retrospectively compare clinical outcomes for patients with AF in Italy (overall and by age group) who received edoxaban versus apixaban.

Conclusion: IS/SE risk was significantly lower for edoxaban versus apixaban, without an increased MB risk among patients with Atrial Fibrillation overall and those aged 80 years.

IS = ischaemic stroke, SE = systemic embolism, MB=major bleeding

Full length article:

https://doi.org/10.1055/a-2822-9746

https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-2822-9746.pdf

reddit.com
u/Run-neR — 18 days ago
▲ 1 r/AFIB

Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study [2022]

Background: The aim of the study was to compare the real-world effectiveness and safety in atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants (OACs) (apixaban, dabigatran, rivaroxaban, and vitamin K antagonists [VKA]) in Germany.

Conclusions: Edoxaban was associated with better effectiveness compared with other OACs in AF patients from Germany. Edoxaban also demonstrated a favorable safety profile.

Full length article: https://pubmed.ncbi.nlm.nih.gov/34780886/

u/Run-neR — 18 days ago